David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared on LinkedIn:
”And another good piece of news for our HER2-mutated NSCLC patients.
Enhertu, first ADC as 1L monotherapy… a new 1L standard of care HER2 mutant NSCLC? Awaiting full results.”
AstraZeneca and Daiichi Sankyo’s Enhertu Improves PFS in First-Line HER2-Mutant Advanced NSCLC in Phase III DESTINY-Lung04
Other articles about lung cancer on OncoDaily.